biostudies-literatureMcLean RKBiotechnology and Biological Sciences Research Council,United KingdomInnovate UK,United KingdomBiotechnology and Biological Sciences Research Council163https://www.ebi.ac.uk/biostudies/studies/S-EPMC12287429biostudies-literatureUnknown10(1)Nipah virus (NiV) causes a severe neurological disease in humans. The first NiV outbreak, in Malaysia, involved pig-to-human transmission, that resulted in significant economic losses to the local pig industry. Despite the risk NiV poses to pig-dense regions, no licensed vaccines exist. This study therefore assessed three NiV vaccine candidates in pigs: (1) adjuvanted soluble NiV (s)G protein, (2) adjuvanted pre-fusion stabilised NiV (mcs)F protein, and (3) adenoviral vectored NiV G (ChAdOx1 NiV G). NiV sG induced the strongest neutralising antibody response, NiV mcsF induced antibodies best able to neutralise cell-cell fusion, whereas ChAdOx1 NiV G elicited CD8⁺ T-cell responses. Despite differences in immunogenicity, prime-boost immunisation with all candidates conferred a higNPJ vaccinesNipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.PMC12287429971555BBS/E/I/00007039BBS/E/I/00007031Thakur NWatterson DBailey DMarsh GAHodgson SGilbert SCPedrera MRowe BBegum MNReid TIsaacs ABruce MTrinidad LLowther SBergfeld JBhuyan AAMGraham SPLambe TEdwards SRahman MZAu GBarr JChappell KTchilian ELayton RRaue RTodd SMourino MRahman MAlam MRye NYoung PShanta ISSiddika AElrefaey AMEFisher MPoole TRahman SMcLean RKPayne JRiddell SBrown SDalziel TfalseNipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.Nipah virus (NiV) causes a severe neurological disease in humans. The first NiV outbreak, in Malaysia, involved pig-to-human transmission, that resulted in significant economic losses to the local pig industry. Despite the risk NiV poses to pig-dense regions, no licensed vaccines exist. This study therefore assessed three NiV vaccine candidates in pigs: (1) adjuvanted soluble NiV (s)G protein, (2) adjuvanted pre-fusion stabilised NiV (mcs)F protein, and (3) adenoviral vectored NiV G (ChAdOx1 NiV G). NiV sG induced the strongest neutralising antibody response, NiV mcsF induced antibodies best able to neutralise cell-cell fusion, whereas ChAdOx1 NiV G elicited CD8⁺ T-cell responses. Despite differences in immunogenicity, prime-boost immunisation with all candidates conferred a hig2025-01-01T00:00:00Z2025 Jul2026-07-15T14:14:25.802Z2025-08-17T03:05:54.049ZS-EPMC122874294070201210.1038/s41541-025-01212-y